中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.016 seconds)

    Treatment of alphavirus-induced inflammation
    1.
    发明授权
    Treatment of alphavirus-induced inflammation 有权

    公开(公告)号：US11638718B2

    公开(公告)日：2023-05-02

    申请号：US16884628

    申请日：2020-05-27

    Applicant: GRIFFITH UNIVERSITY

    Inventor： Surendran Mahalingam ,  Lara Josefina Herrero

    IPC: A61K31/737 ,  A61P19/02 ,  A61P31/14 ,  A61P29/00 ,  A61K9/00

    Abstract: Disclose is a method of treating alphavirus infections, particularly in humans, in which pentosan polysulfate is administered to an infected subject. Whilst not effecting the viral load in a subject, the pentosan polysulfate acts to reduce inflammation in tissues, such as the muscles, and in the joints of a subject. In addition, cartilage damage in the joints may be reduced. The reduction in inflammation and/or cartilage damage acts to reduce the severe pain experienced by subjects suffering from alphavirus infections, such as Ross River virus, chikungunya virus and Barmah Forest virus.

    VIRUS VACCINE
    2.
    发明申请
    VIRUS VACCINE 有权

    公开(公告)号：US20220088169A1

    公开(公告)日：2022-03-24

    申请号：US17285045

    申请日：2019-10-15

    Applicant: Griffith University ,  University of Tartu

    Inventor： Surendran Mahalingam ,  Andres Merits ,  Eva Zusinaite

    IPC: A61K39/12 ,  A61P31/14 ,  C12N7/00 ,  A61K39/00

    Abstract: This invention relates to a vaccine comprising live attenuated Zika virus comprising a partly codon deoptimized viral genome, a Zika virus comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. is deoptimized along the nonstructural ZIKV coding region. In some embodiments, the non-structural region of the viral genome is codon deoptimized, and preferably one or more of the genes NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are codon deoptimized.

    TREATMENT OF ALPHAVIRUS-INDUCED INFLAMMATION
    4.
    发明申请
    TREATMENT OF ALPHAVIRUS-INDUCED INFLAMMATION 审中-公开

    公开(公告)号：US20190255097A1

    公开(公告)日：2019-08-22

    申请号：US16304550

    申请日：2016-05-26

    Applicant: GRIFFITH UNIVERSITY

    Inventor： Surendran Mahalingam ,  Lara Josefina Herrero

    IPC: A61K31/737 ,  A61K9/00 ,  A61P31/14 ,  A61P19/02 ,  A61P29/00

    Abstract: Disclosed is a method of treating alphavirus infections, particularly in humans, in which pentosan polysulfate is administered to an infected subject. Whilst not effecting the viral load in a subject, the pentosan polysulfate acts to reduce inflammation in tissues, such as the muscles, and in the joints of a subject. In addition, cartilage damage in the joints may be reduced. The reduction in inflammation and/or cartilage damage acts to reduce the severe pain experienced by subjects suffering from alphavirus infections, such as Ross River virus, chikungunya virus and Barmah Forest virus.

    ARTHROGENIC ALPHAVIRUS VACCINE
    5.
    发明申请
    ARTHROGENIC ALPHAVIRUS VACCINE 审中-公开

    公开(公告)号：US20190134197A1

    公开(公告)日：2019-05-09

    申请号：US16304509

    申请日：2017-05-25

    Applicant: GRIFFITH UNIVERSITY

    Inventor： Surendran Mahalingam ,  Adam Taylor

    IPC: A61K39/42 ,  A61P31/14 ,  A61K39/12

    Abstract: The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would otherwise produce clinical signs of disease. In an embodiment the mutated capsid protein is Chikungunya virus (CHIKV) capsid protein having a mutated nucleolar localisation signal/sequence (NoLS), preferably the mutant NLS 101/95.

Patent Agency Ranking